NCT05161598No Longer Available不适用
PRE-APPROVAL ACCESS (PAA) Single Patient Request (SPR) TREATMENT GUIDELINES for Teclistamab (JNJ-64007957) for Treating Physician Use
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
Teclistamab pre-approval access in relapsed or refractory multiple myeloma.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple MyelomaMultiple Myeloma in RelapseMultiple MyelomaNCT02666209Dana-Farber Cancer Institute
Unknown
不适用
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05503550Janssen Research & Development, LLC
Available
不适用
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Metastatic Castration-Resistant Prostate CancerNCT05650476Pfizer
No Longer Available
不适用
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)Multiple MyelomaNCT05238311Pfizer
Approved For Marketing
不适用
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01632826Celgene